The tweet was deleted by the author.
But we saved everything 🙂.
Artiva Biotherapeutics, Inc. has announced positive initial clinical results for its AlloNK cell therapy across multiple autoimmune diseases.
The company also shared that it reached alignment with the U.S. Food and Drug Administration regarding plans to initiate a Phase 3 registrational trial targeting refractory rheumatoid arthritis in 2026. These early findings bolster the therapeutic potential of AlloNK as a treatment option for patients with challenging autoimmune conditions. Further details about the trial timeline and protocol are expected as preparations advance.